Lamprini Veneti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lamprini Veneti has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
Karoline Bragstad
Department of Virology, Norwegian Institute of Public Health, Oslo, Norway
6 shared publicationsOlav Hungnes
Department of Virology, Norwegian Institute of Public Health, Oslo, Norway
6 shared publicationsElina Seppälä
Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway
4 shared publicationsHinta Meijerink
Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway
4 shared publications- Håkon Bøås
Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway
4 shared publications - Jostein Starrfelt
Department of Infection Control and Preparedness, Norwegian Institute of Public Health, Oslo, Norway
4 shared publications
Latest Publications
- Open Access
- 27 May 2025
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 44 (9) , 2047-2057
Risk factors associated with long-term shedding infections of non-typhoidal Salmonella in humans
Purpose: Non-typhoidal Salmonella (NTS) gastroenteritis in humans is typically self-limited, resolving within 48–72 h. However, some infections result in a carrier state characterised by persistent gut colonisation and long-term shedding (LTS). This study aimed to investigate risk factors associated with LTS of NTS in humans. Methods: Salmonellosis cases reported to the Norwegian surveillance system in 2019 were invited to participate. Participants submitted a follow-up stool sample and a questionnaire five weeks after initial sampling (detecting infection). Stool samples were cultured, and isolates were sequenced to determine genotype, serotype and antimicrobial resistance genotype. NTS cases were classified as LTS if the isolates from both samples differed by ≤ 5 alleles. Adjusted odds ratios (aORs) with 95% confidence intervals (95%CIs) were calculated using logistic regression to investigate potential risk factors associated with LTS. Results: Of 1,094 reported cases, 255 (23%) with NTS participated; 24% were classified as LTS. Children aged 0–5 years were 6.7 times more likely to exhibit LTS compared to adults aged 18–44 years (aOR = 6.71, 95%CI:1.67–26.94). Participants who received regular medication and those following a lactose-free diet were 2.2 (aOR = 2.17, 95%CI:1.02–4.64) and 7.2 (aOR = 7.24, 95%CI:1.48–35.40) times more likely to exhibit LTS than those who did not, respectively. Participants with S. Agbeni or S. Bron were 6 times more likely to exhibit LTS compared to S. Typhimurium cases (aOR = 6.29, 95%CI:1.40–28.16). Conclusions: Observed risk factors associated with LTS included young age, regular medication use, lactose-free diet, and specific Salmonella serotypes. Further research is needed to increase knowledge regarding LTS and inform infection control measures.
- 27 May 2025
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 44 (9) , 2047-2057
Open AccessRisk factors associated with long-term shedding infections of non-typhoidal Salmonella in humans
Purpose: Non-typhoidal Salmonella (NTS) gastroenteritis in humans is typically self-limited, resolving within 48–72 h. However, some infections result in a carrier state characterised by persistent gut colonisation and long-term shedding (LTS). This study aimed to investigate risk factors associated with LTS of NTS in humans. Methods: Salmonellosis cases reported to the Norwegian surveillance system in 2019 were invited to participate. Participants submitted a follow-up stool sample and a questionnaire five weeks after initial sampling (detecting infection). Stool samples were cultured, and isolates were sequenced to determine genotype, serotype and antimicrobial resistance genotype. NTS cases were classified as LTS if the isolates from both samples differed by ≤ 5 alleles. Adjusted odds ratios (aORs) with 95% confidence intervals (95%CIs) were calculated using logistic regression to investigate potential risk factors associated with LTS. Results: Of 1,094 reported cases, 255 (23%) with NTS participated; 24% were classified as LTS. Children aged 0–5 years were 6.7 times more likely to exhibit LTS compared to adults aged 18–44 years (aOR = 6.71, 95%CI:1.67–26.94). Participants who received regular medication and those following a lactose-free diet were 2.2 (aOR = 2.17, 95%CI:1.02–4.64) and 7.2 (aOR = 7.24, 95%CI:1.48–35.40) times more likely to exhibit LTS than those who did not, respectively. Participants with S. Agbeni or S. Bron were 6 times more likely to exhibit LTS compared to S. Typhimurium cases (aOR = 6.29, 95%CI:1.40–28.16). Conclusions: Observed risk factors associated with LTS included young age, regular medication use, lactose-free diet, and specific Salmonella serotypes. Further research is needed to increase knowledge regarding LTS and inform infection control measures.
- Open Access
Changed epidemiology of influenza and RSV hospitalizations after the emergence of SARS-CoV-2 in Norway, 2017 - 2024
Background Many countries reported missing and atypical influenza and RSV seasons during the COVID-19 pandemic. Here we describe the incidence and seasonality of COVID-19, influenza, and RSV hospitalizations in Norway between 2017-2024, and the disease burden between 2022-2024. Methods Using nationwide data on ICD-10 discharge codes, procedure codes and laboratory results, we calculate the incidence of COVID-19, influenza, and RSV hospitalizations, by age group, week and season between January 2017 to April 2024, and report proportions receiving intensive care, proportion of deaths and length of stay between 2022-2024. Results The transmission of influenza and RSV was interrupted the first year of the COVID-19 pandemic and reemerged with epidemics outside of the normal seasonality in 2021/2022, after COVID-19 restrictions were removed. Between 2022-2024, COVID-19 was a greater contributor to hospitalizations than influenza and RSV, with higher mortality rate within two weeks of admission. The use of ventilatory support/intensive care admission was highest among patients hospitalized with RSV. Conclusion The transmission of influenza and RSV was interrupted during the first year of the COVID-19 pandemic, followed by an unusual seasonality. Although many hospitalizations are caused by RSV and influenza, COVID-19 was the largest contributor of these three to hospital burden in the first years with co-circulation.
Open AccessChanged epidemiology of influenza and RSV hospitalizations after the emergence of SARS-CoV-2 in Norway, 2017 - 2024
Background Many countries reported missing and atypical influenza and RSV seasons during the COVID-19 pandemic. Here we describe the incidence and seasonality of COVID-19, influenza, and RSV hospitalizations in Norway between 2017-2024, and the disease burden between 2022-2024. Methods Using nationwide data on ICD-10 discharge codes, procedure codes and laboratory results, we calculate the incidence of COVID-19, influenza, and RSV hospitalizations, by age group, week and season between January 2017 to April 2024, and report proportions receiving intensive care, proportion of deaths and length of stay between 2022-2024. Results The transmission of influenza and RSV was interrupted the first year of the COVID-19 pandemic and reemerged with epidemics outside of the normal seasonality in 2021/2022, after COVID-19 restrictions were removed. Between 2022-2024, COVID-19 was a greater contributor to hospitalizations than influenza and RSV, with higher mortality rate within two weeks of admission. The use of ventilatory support/intensive care admission was highest among patients hospitalized with RSV. Conclusion The transmission of influenza and RSV was interrupted during the first year of the COVID-19 pandemic, followed by an unusual seasonality. Although many hospitalizations are caused by RSV and influenza, COVID-19 was the largest contributor of these three to hospital burden in the first years with co-circulation.
- Open Access
- 29 May 2024
- Published by Springer Nature in BMC Public Health
- Vol. 24 (1) , 1-18
Social contact patterns during the early COVID-19 pandemic in Norway: insights from a panel study, April to September 2020
Background: During the COVID-19 pandemic, many countries adopted social distance measures and lockdowns of varying strictness. Social contact patterns are essential in driving the spread of respiratory infections, and country-specific measurements are needed. This study aimed to gain insights into changes in social contacts and behaviour during the early pandemic phase in Norway. Methods: We conducted an online panel study among a nationally representative sample of Norwegian adults by age and gender. The panel study included six data collections waves between April and September 2020, and 2017 survey data from a random sample of the Norwegian population (including children < 18 years old) were used as baseline. The market research company Ipsos was responsible for carrying out the 2020 surveys. We calculated mean daily contacts, and estimated age-stratified contact matrices during the study period employing imputation of child-to-child contacts. We used the next-generation method to assess the relative reduction of R0 and compared the results to reproduction numbers estimated for Norway during the 2020 study period. Results: Over the six waves in 2020, 5 938 observations/responses were registered from 1 718 individuals who reported data on 22 074 contacts. The mean daily number of contacts among adults varied between 3.2 (95%CI 3.0-3.4) to 3.9 (95%CI 3.6–4.2) across the data collection waves, representing a 67–73% decline compared to pre-pandemic levels (baseline). Fewer contacts in the community setting largely drove the reduction; the drop was most prominent among younger adults. Despite gradual easing of social distance measures during the survey period, the estimated population contact matrices remained relatively stable and displayed more inter-age group mixing than at baseline. Contacts within households and the community outside schools and workplaces contributed most to social encounters. Using the next-generation method R0 was found to be roughly 25% of pre-pandemic levels during the study period, suggesting controlled transmission. Conclusion: Social contacts declined significantly in the months following the March 2020 lockdown, aligning with implementation of stringent social distancing measures. These findings contribute valuable empirical information into the social behaviour in Norway during the early pandemic, which can be used to enhance policy-relevant models for addressing future crises when mitigation measures might be implemented.
- 29 May 2024
- Published by Springer Nature in BMC Public Health
- Vol. 24 (1) , 1-18
Open AccessSocial contact patterns during the early COVID-19 pandemic in Norway: insights from a panel study, April to September 2020
Background: During the COVID-19 pandemic, many countries adopted social distance measures and lockdowns of varying strictness. Social contact patterns are essential in driving the spread of respiratory infections, and country-specific measurements are needed. This study aimed to gain insights into changes in social contacts and behaviour during the early pandemic phase in Norway. Methods: We conducted an online panel study among a nationally representative sample of Norwegian adults by age and gender. The panel study included six data collections waves between April and September 2020, and 2017 survey data from a random sample of the Norwegian population (including children < 18 years old) were used as baseline. The market research company Ipsos was responsible for carrying out the 2020 surveys. We calculated mean daily contacts, and estimated age-stratified contact matrices during the study period employing imputation of child-to-child contacts. We used the next-generation method to assess the relative reduction of R0 and compared the results to reproduction numbers estimated for Norway during the 2020 study period. Results: Over the six waves in 2020, 5 938 observations/responses were registered from 1 718 individuals who reported data on 22 074 contacts. The mean daily number of contacts among adults varied between 3.2 (95%CI 3.0-3.4) to 3.9 (95%CI 3.6–4.2) across the data collection waves, representing a 67–73% decline compared to pre-pandemic levels (baseline). Fewer contacts in the community setting largely drove the reduction; the drop was most prominent among younger adults. Despite gradual easing of social distance measures during the survey period, the estimated population contact matrices remained relatively stable and displayed more inter-age group mixing than at baseline. Contacts within households and the community outside schools and workplaces contributed most to social encounters. Using the next-generation method R0 was found to be roughly 25% of pre-pandemic levels during the study period, suggesting controlled transmission. Conclusion: Social contacts declined significantly in the months following the March 2020 lockdown, aligning with implementation of stringent social distancing measures. These findings contribute valuable empirical information into the social behaviour in Norway during the early pandemic, which can be used to enhance policy-relevant models for addressing future crises when mitigation measures might be implemented.
- Open Access
Social contact patterns during the early COVID-19 pandemic in Norway: insights from a panel study, April to September 2020
Background During the COVID-19 pandemic, many countries adopted social distance measures and lockdowns of varying strictness. Social contact patterns are essential in driving the spread of respiratory infections, and country-specific measurements are needed. This study aimed to gain insights into changes in social contacts and behaviour during the early pandemic phase in Norway. Methods We conducted an online survey among a nationally representative sample of Norwegian adults, including six data collections/waves between April and September 2020, and used survey data from 2017 as baseline. We calculated mean daily contacts, and estimated age-stratified contact matrices that were used to estimate reproduction numbers during the study period. Results The mean daily number of contacts varied between 3.2 (95% CI 3.0-3.4) to 3.9 (95% CI 3.6-4.2) across waves, representing a 67-73% decline compared to pre-pandemic levels. Fewer contacts in the community setting largely drove the reduction; the drop was most prominent among younger adults. Despite gradual easing of social distance measures during the survey period, population contact matrices remained relatively stable and displayed more inter-age group mixing than at baseline. Contacts within households and the community outside schools and workplaces contributed most to social encounters. Conclusion Social contacts experienced a significant decline during the months following the March 2020 lockdown in Norway, aligning with the implementation of stringent social distancing measures. The findings contribute valuable empirical information into the social behaviour of the Norwegian population during the early pandemic, which can be used to enhance policy-relevant models for addressing future crises when mitigation measures might be implemented.
Open AccessSocial contact patterns during the early COVID-19 pandemic in Norway: insights from a panel study, April to September 2020
Background During the COVID-19 pandemic, many countries adopted social distance measures and lockdowns of varying strictness. Social contact patterns are essential in driving the spread of respiratory infections, and country-specific measurements are needed. This study aimed to gain insights into changes in social contacts and behaviour during the early pandemic phase in Norway. Methods We conducted an online survey among a nationally representative sample of Norwegian adults, including six data collections/waves between April and September 2020, and used survey data from 2017 as baseline. We calculated mean daily contacts, and estimated age-stratified contact matrices that were used to estimate reproduction numbers during the study period. Results The mean daily number of contacts varied between 3.2 (95% CI 3.0-3.4) to 3.9 (95% CI 3.6-4.2) across waves, representing a 67-73% decline compared to pre-pandemic levels. Fewer contacts in the community setting largely drove the reduction; the drop was most prominent among younger adults. Despite gradual easing of social distance measures during the survey period, population contact matrices remained relatively stable and displayed more inter-age group mixing than at baseline. Contacts within households and the community outside schools and workplaces contributed most to social encounters. Conclusion Social contacts experienced a significant decline during the months following the March 2020 lockdown in Norway, aligning with the implementation of stringent social distancing measures. The findings contribute valuable empirical information into the social behaviour of the Norwegian population during the early pandemic, which can be used to enhance policy-relevant models for addressing future crises when mitigation measures might be implemented.
- Open Access
- 7 March 2023
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 130, 182-188
Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022
- 7 March 2023
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 130, 182-188
Open AccessEffectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022
- Open Access
Vaccine effectiveness with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine against reported SARS-CoV-2 Delta and Omicron infection among adolescents, Norway, August 2021 to January 2022
Background COVID-19 vaccination was recommended for adolescents in Norway since August 2021. In this population-based cohort study, we estimated the BNT162b2 vaccine effectiveness against any PCR-confirmed (symptomatic or not) SARS-CoV-2 infections caused by the Delta and Omicron variant among adolescents (12-17-years-old) in Norway from August 2021 to January 2022. Methods Using Cox proportional hazard models, we estimated the BNT162b2 vaccine effectiveness against any Delta and Omicron infections. Vaccine status was included as a time-varying covariate and models were adjusted for age, sex, comorbidities, county of residence, country of birth, and living conditions. Data were obtained from the National Preparedness registry for COVID-19, which contains individual-level data from national health and administrative registries. Findings Vaccine effectiveness against Delta infection peaked at 68% (95%CI: 64–71%) and 62% (95%CI: 57– 66%) in days 21-48 after the first dose among 12–15-year-olds and 16–17-year-olds respectively. Among 16–17-year-olds that received two doses, vaccine effectiveness peaked at 93% (95%CI: 90–95%) in days 35-62 and declined to 84% (95%CI: 76–89%) in 63 days or more after the second dose. For both age-groups, we found no protection against Omicron infection after receiving one dose. Among 16–17-year-olds, vaccine effectiveness against Omicron infection peaked at 53% (95%CI: 43–62%) in 7-34 days after the second dose and decreased to 23% (95%CI: 3–40%) in 63 days or more after vaccination. Vaccine effectiveness decreased with time since vaccination for both variants, but waning was observed to occur faster for Omicron. Interpretation Our results suggest reduced protection from BNT162b2 vaccination against any SARS-CoV-2 infection caused by the Omicron variant compared to the Delta. In addition, waning immunity was observed to occur faster for Omicron. The impact of vaccination among adolescents on reducing infection and thus transmission is limited during omicron dominance. Funding No funding was received. Evidence before this study BNT162b2 (Comirnaty, Pfizer-BioNTech) and mRNA-1273 (Spikevax, Moderna) vaccines have been approved for use in adolescents, based on results from randomized placebo-controlled trials demonstrating comparable immunogenicity and safety profile as in young adults. In addition, observational studies from Israel, the USA and England have reported high protection of BNT162b2 vaccines against SARS-CoV-2 Delta infection among adolescents. These studies also reported decrease in effectiveness with time since last vaccine dose. Evidence on the effect of an extended interval between doses, longer time since vaccination and the effect against different variants is limited. When we first planned this study in early February 2022, no data were available regarding vaccine effectiveness against SARS-CoV-2 Omicron infection among adolescents. To our knowledge when we completed this study and before submitting this article, only one study from England reported results in a preprint on vaccine effectiveness against symptomatic SARS-CoV-2 Omicron infection among adolescents. We searched for studies that evaluated vaccine efficacy or effectiveness after vaccination of adolescents during 2021-2022 in PubMed, medRxiv, bioRxiv, SSRN. We searched for studies with several variations of the primary key search terms “COVID-19”, “SARS-CoV-2”, and “vaccine” (including names of specific vaccines, as BNT162b2), “vaccine effectiveness”, “adolescents”, “children”. Added value of this study The rapid increase in the incidence of SARS-CoV-2 infection caused by the Omicron variant in highly vaccinated populations has raised concerns about the effectiveness of current vaccines in adults but also adolescents. In this population-based cohort study, we showed that the vaccine effectiveness against Omicron is lower than against Delta infections among adolescents, including symptomatic and asymptomatic infections. We should note that evidence suggests higher rates of asymptomatic carriage for Omicron than other variants of concern. Vaccine effectiveness that includes asymptomatic cases, as in the study from England, is expected to be lower than when including symptomatic cases only. We found that one and two doses of BNT162b2 among adolescents protected well against Delta. Vaccination provided high protection against Delta infections (>91%) among Norwegian 16-17-year-olds 7-62 days after the second dose. We found no protection against Omicron SARS-CoV-2 infection after one vaccine dose, and moderate effectiveness after two doses (peaked at 53%) among the 16-17-year-olds. Moreover, waning immunity was observed to occur faster for Omicron. Implications of all the available evidence Based on the available evidence, the vaccine effectiveness among adolescents is similar to that reported among adults, also with an extended period of 8-12 weeks between doses which was used in Norway. Protection is significantly lower against Omicron than Delta infections and immunity wanes faster against Omicron. The impact of vaccination among adolescents on reducing infection and thus transmission is limited during omicron dominance. Policies should take into account the impact of vaccination campaigns among adolescents and their primary objective. Vaccine effectiveness should be re-evaluated when other variants appear as they might have different outcomes as shown between Delta and Omicron infections.
Open AccessVaccine effectiveness with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine against reported SARS-CoV-2 Delta and Omicron infection among adolescents, Norway, August 2021 to January 2022
Background COVID-19 vaccination was recommended for adolescents in Norway since August 2021. In this population-based cohort study, we estimated the BNT162b2 vaccine effectiveness against any PCR-confirmed (symptomatic or not) SARS-CoV-2 infections caused by the Delta and Omicron variant among adolescents (12-17-years-old) in Norway from August 2021 to January 2022. Methods Using Cox proportional hazard models, we estimated the BNT162b2 vaccine effectiveness against any Delta and Omicron infections. Vaccine status was included as a time-varying covariate and models were adjusted for age, sex, comorbidities, county of residence, country of birth, and living conditions. Data were obtained from the National Preparedness registry for COVID-19, which contains individual-level data from national health and administrative registries. Findings Vaccine effectiveness against Delta infection peaked at 68% (95%CI: 64–71%) and 62% (95%CI: 57– 66%) in days 21-48 after the first dose among 12–15-year-olds and 16–17-year-olds respectively. Among 16–17-year-olds that received two doses, vaccine effectiveness peaked at 93% (95%CI: 90–95%) in days 35-62 and declined to 84% (95%CI: 76–89%) in 63 days or more after the second dose. For both age-groups, we found no protection against Omicron infection after receiving one dose. Among 16–17-year-olds, vaccine effectiveness against Omicron infection peaked at 53% (95%CI: 43–62%) in 7-34 days after the second dose and decreased to 23% (95%CI: 3–40%) in 63 days or more after vaccination. Vaccine effectiveness decreased with time since vaccination for both variants, but waning was observed to occur faster for Omicron. Interpretation Our results suggest reduced protection from BNT162b2 vaccination against any SARS-CoV-2 infection caused by the Omicron variant compared to the Delta. In addition, waning immunity was observed to occur faster for Omicron. The impact of vaccination among adolescents on reducing infection and thus transmission is limited during omicron dominance. Funding No funding was received. Evidence before this study BNT162b2 (Comirnaty, Pfizer-BioNTech) and mRNA-1273 (Spikevax, Moderna) vaccines have been approved for use in adolescents, based on results from randomized placebo-controlled trials demonstrating comparable immunogenicity and safety profile as in young adults. In addition, observational studies from Israel, the USA and England have reported high protection of BNT162b2 vaccines against SARS-CoV-2 Delta infection among adolescents. These studies also reported decrease in effectiveness with time since last vaccine dose. Evidence on the effect of an extended interval between doses, longer time since vaccination and the effect against different variants is limited. When we first planned this study in early February 2022, no data were available regarding vaccine effectiveness against SARS-CoV-2 Omicron infection among adolescents. To our knowledge when we completed this study and before submitting this article, only one study from England reported results in a preprint on vaccine effectiveness against symptomatic SARS-CoV-2 Omicron infection among adolescents. We searched for studies that evaluated vaccine efficacy or effectiveness after vaccination of adolescents during 2021-2022 in PubMed, medRxiv, bioRxiv, SSRN. We searched for studies with several variations of the primary key search terms “COVID-19”, “SARS-CoV-2”, and “vaccine” (including names of specific vaccines, as BNT162b2), “vaccine effectiveness”, “adolescents”, “children”. Added value of this study The rapid increase in the incidence of SARS-CoV-2 infection caused by the Omicron variant in highly vaccinated populations has raised concerns about the effectiveness of current vaccines in adults but also adolescents. In this population-based cohort study, we showed that the vaccine effectiveness against Omicron is lower than against Delta infections among adolescents, including symptomatic and asymptomatic infections. We should note that evidence suggests higher rates of asymptomatic carriage for Omicron than other variants of concern. Vaccine effectiveness that includes asymptomatic cases, as in the study from England, is expected to be lower than when including symptomatic cases only. We found that one and two doses of BNT162b2 among adolescents protected well against Delta. Vaccination provided high protection against Delta infections (>91%) among Norwegian 16-17-year-olds 7-62 days after the second dose. We found no protection against Omicron SARS-CoV-2 infection after one vaccine dose, and moderate effectiveness after two doses (peaked at 53%) among the 16-17-year-olds. Moreover, waning immunity was observed to occur faster for Omicron. Implications of all the available evidence Based on the available evidence, the vaccine effectiveness among adolescents is similar to that reported among adults, also with an extended period of 8-12 weeks between doses which was used in Norway. Protection is significantly lower against Omicron than Delta infections and immunity wanes faster against Omicron. The impact of vaccination among adolescents on reducing infection and thus transmission is limited during omicron dominance. Policies should take into account the impact of vaccination campaigns among adolescents and their primary objective. Vaccine effectiveness should be re-evaluated when other variants appear as they might have different outcomes as shown between Delta and Omicron infections.
- Open Access
- 5 February 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 118, 34-43
Severity of the clinical presentation of hepatitis A in five European countries from 1995 to 2014
- 5 February 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 118, 34-43
Open AccessSeverity of the clinical presentation of hepatitis A in five European countries from 1995 to 2014
- Top Cited PapersOpen Access
- 27 January 2022
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 27 (4) , 2200077
Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022
We included 39,524 COVID-19 Omicron and 51,481 Delta cases reported in Norway from December 2021 to January 2022. We estimated a 73% reduced risk of hospitalisation (adjusted hazard ratio: 0.27; 95% confidence interval: 0.20–0.36) for Omicron compared with Delta. Compared with unvaccinated groups, Omicron cases who had completed primary two-dose vaccination 7–179 days before diagnosis had a lower reduced risk than Delta (66% vs 93%). People vaccinated with three doses had a similar risk reduction (86% vs 88%).
- 27 January 2022
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 27 (4) , 2200077
Top Cited PapersOpen AccessReduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022
We included 39,524 COVID-19 Omicron and 51,481 Delta cases reported in Norway from December 2021 to January 2022. We estimated a 73% reduced risk of hospitalisation (adjusted hazard ratio: 0.27; 95% confidence interval: 0.20–0.36) for Omicron compared with Delta. Compared with unvaccinated groups, Omicron cases who had completed primary two-dose vaccination 7–179 days before diagnosis had a lower reduced risk than Delta (66% vs 93%). People vaccinated with three doses had a similar risk reduction (86% vs 88%).